Clinical care · Life science

The data exists.
We make it searchable.

Longitudinal patient records from German ambulatory care, structured and made accessible for efficient research.

CLINICAL CARE
practices · clinics · labs
LIFE SCIENCE
pharma · biotech · CROs
1 patient record · 83 diagnoses · 68 therapies · 99+ laboratory values
Fig. 1 · One record becoming structured data. All values synthetic.
What can YOU ask

Ask why. Not just how many.

Every answer traces back to one document, on one page, written by the physician who treated the patient.

why

The documented reason a therapy was started, changed or held.

full picture

Confirmed findings and excluded findings, both recorded, both searchable.

full history

General practice records going back years before a specialist opens the file.

What is in one record

One record. As the practice documented it.

One patient, as the practice documented them. Every value carries the document it was read from, the page, and whether it was reviewed.

Clinical letters 1
Diagnoses 83
Therapy 68
Medication 36
Radiology 71
Laboratory 99+
Histology 9
Treatment plan 42
Staging 5
Vitals 2
Molecular pathology
Immunohistochemistry
First seen
Diagnosis
Certainty
ICD-10
Source
2023-06-01
Urethral stricture, laterality bilateral
Confirmed
N35.9
p. 2
2021-03-01
Pembrolizumab-induced myocarditis
Confirmed
I51.4
p. 2
2020-10-01
Long-term double-J stenting for bilateral hydronephrosis in acinar adenocarcinoma of the prostate, Gleason 4+5
Confirmed
C61
p. 1
not stated
Generalised atherosclerosis
Confirmed
I70.9
p. 1
not stated
Abdominal aortic aneurysm
Excluded
I71.4
p. 1
not stated
Carotid artery stenosis, laterality bilateral
Excluded
I65.2
p. 1
2025-11-28 · CLINICAL LETTER
[redacted]
[redacted]
Exclusion of peripheral arterial disease of the lower extremities, bilateral. Exclusion of carotid artery stenosis, bilateral.
[redacted]
[redacted]
Fig. 2 · One patient record with source linkage. All values synthetic, identifying data redacted.

Green is what the physician confirmed. Red is what the physician excluded. Both are in the file, and both are searchable.

ICD-10-GM · ICD-O-3 · ATC · LOINC · UCUM · MedDRA
Longitudinal depth

One patient. Eight years. Each visit.

A hospital dataset holds the episode. A claims database holds the invoice. The ambulatory file holds the years in between.

FIRST PRESENTATION · GENERAL PRACTICEREFERRAL TO SPECIALISTENCOUNTERSLABORATORYTHERAPYLINE 1LINE 2Reason documented: intolerance,recorded in the letter of 2023-04-11.201620172018201920202021202220232024
Fig. 3 · Eight years of one synthetic patient. Illustrative.
The bridge

When a record becomes a cohort.

01
Indication·Type 2 diabetes with established cardiovascular disease
12,480
02
Demographics·Age 60 to 80
7,240
03
Laboratory·HbA1c above 7.5 % in the last 12 months
3,890
04
Therapy·On metformin, no SGLT2 inhibitor
1,660
05
Documented rationale·A reason recorded for the therapy decision
412

This filter runs on the primary documentation, including the free text in it.

Fig. 4 · Synthetic demonstration. These are not network counts.
What you get

A report. Not a login.

An answer you can take into your next internal meeting, with the reasoning attached.

Counts with n

Cohort sizes against your criteria, distributions, and completeness per variable, so you can see whether an endpoint is supportable.

The reasoning

How we arrived at each number, written in the same document as the number.

A slide version

So you can present it without rebuilding it.

Scope depends on the question: how many patients, how deep, over what period. We tell you in one call what it takes.
Where MPIRIQ delivers

Three questions. One source.

Check protocol feasibility
01

Know your cohort before you start. We run your criteria against documented records, criterion by criterion, and show the drop-off at each step. Enrolment planned against documentation, not estimates.

Secure your endpoint
02

When an endpoint depends on a variable your current source does not carry, we tell you on the first call whether the physician documented it, and where.

Go beyond claims
03

Claims data shows you that something happened. The clinical record shows you why, in the documentation itself, with the source behind every value.

Tell us your question. On the first call we tell you whether the data can answer it. The counts follow once we have your criteria.

How this starts

You will know after one conversation.

01
A named reply

A named person who can read your question answers it.

02
A scoping call

We tell you what the data supports for your specific question.

03
Your own indication

Under NDA you see real structured records for your cohort, with a link to the source for every value.

What never leaves the practice

Every value traces to its page. No value traces to a person.

Records are de-identified at source, inside the practice. No personal data ever reaches our infrastructure.

IDENTIFYING DATA STOPS HEREPRACTICEDE-IDENTIFIED AT SOURCEMPIRIQ
Fig. 5 · Processing architecture.
De-identified at source

It happens in the practice, under the physician's duty of confidentiality, before any record enters our infrastructure.

Keys stay with the practice

De-identification happens before any transmission. We never receive a key, and we never hold personal data.

German law, German servers

Art. 9(2)(j) GDPR, § 27 BDSG, § 6 GDNG, under Art. 28 GDPR, with an external legal opinion. Data residency Germany.

Two applications

Same record. Two questions.

Clinical trials
Eligible patients are already documented in the record.
For Clinical Operations and Study Management.
See how we identify patients
Real-world evidence
What was decided, not what was billed.
For Medical Affairs, pre-HTA feasibility and commercial intelligence.
See how the evidence is built
Who stands behind it

Named people. Named methods.

Markus Haug
Markus Haug
Founder & CEO
20+ years in leadership, company building and consulting.
Dr. Florian Schröder
Dr. Florian Schröder
Founder & CTO
PhD in Quantum Physics, University of Cambridge. Data scientist.
Marta Chodorek
Marta Chodorek
Business Development & Commercial Advisor
15+ years in global pharma business development, specialising in go-to-market strategy, real-world data commercialisation, and advancing personalised medicine.
Matthias Diener
Matthias Diener
Platform Lead Rheumatology
8+ years in Digital Health, specializing in Rheumatology, Go-to-Market and Business Development.
Dr. Hella Mühlbauer
Dr. Hella Mühlbauer
Senior Manager, Pharma Relations
30 years in feasibility studies, CROs, monitoring and eTMF.
Ian Rentsch
Ian Rentsch
Chair, Scientific Advisory Board
25+ years in biopharma, real-world data and healthcare innovation.
Dr. Folma Maren Kiser
Dr. Folma Maren Kiser
Scientific Advisor
Global executive leader and commercial strategist with a legal background, driving digital and AI transformation.
Named, not anonymous
The full team.
Physicians, data scientists and engineers behind every study.
Methods
Target trial emulation
The default design, not a query
New-user active comparator
With propensity score matching or IPTW
ICH E9(R1)
Estimands defined before the analysis
STROBE · RECORD
How every study is reported

Every study gets a protocol and a statistical analysis plan before any data is touched.

Questions we get asked

Questions we get, answered properly.

Why is patient enrolment slower than predicted?

Most recruitment plans rest on two inputs that were never checked against data: a site feasibility questionnaire answered from memory, and a prevalence estimate applied to a catchment population. Both tend to be optimistic in the same direction, and the gap shows up once screening has started and the timeline is already committed.

There is a third reason that is harder to see. Everything needed to apply the criteria sits in the file: the documented reason a therapy changed, whether a condition was actively ruled out, a laboratory trend rather than a single value. Almost none of it is coded, so a site has to read it out of the records by hand, which is accurate and slow. The pool that gets reviewed stays small, and a patient who is only temporarily out of range, and who would qualify after one more laboratory test, is never seen.

In Germany this matters more than elsewhere, because chronic disease is largely managed in ambulatory practice and the years before a specialist diagnosis are documented there. Checking the protocol against records rather than against a questionnaire gives you counts per criterion, the drop-off at each exclusion, and the assumptions written down.

Next stepSend your inclusion and exclusion criteria and we will run them against real records.
What can you do when a study is short of the data it needs?

This is where MPIRIQ is at its strongest. The cohort usually exists and the sites are usually enrolling. What is needed is a variable: the documented reason a therapy changed, whether a condition was actively excluded, a laboratory trend rather than a single value, the years of history before the referral. All four are written down in the primary documentation, which is the layer we read.

Of the routes available at that point, reading the primary documentation is the one that answers questions of this kind. Chart review at the sites is accurate but consumes exactly the site capacity that is already your constraint. Licensing a second claims dataset adds patients. It does not add the variable you are missing.

The first conversation establishes what is documented for your specific question, so you plan against a known answer rather than an assumption.

Next stepSend the endpoint that matters and we will tell you what is documented, and where.
What real-world data sources exist for German primary care?

Four types, and they answer different questions.

Statutory health insurance claims. The broadest coverage in Germany and the standard source for incidence, prevalence and treatment volumes. Built to settle invoices, so it records that something was billed. Diagnoses carry billing intent.

Hospital and university datasets. Deep for the episode of inpatient care and strong where a condition is managed in hospital.

Disease registries and cohort studies. Purpose-built, well defined variables, high data quality per patient, covering the patients who were enrolled.

Ambulatory practice records. The file the physician keeps in order to treat. Complete, because it was written for care rather than for research. This includes general practice and specialist practice, which is why we say ambulatory care rather than primary care.

The fourth is the layer MPIRIQ works in, structured and coded at source with every value linked back to its document.

Next stepSend one indication and we will show you what a record in it contains.
How reliable is primary-care record data for feasibility?

Your team checks the values, not our claim about them. Each structured field keeps a link to the document it was read from, the page it appears on, and whether it was reviewed. The record was written and reviewed by the treating physician, and that link back to it is what you check.

Two properties matter most for feasibility work. Completeness per variable, reported per cohort, because a variable that is 40 per cent complete will not carry an endpoint however accurately it was extracted. And whether exclusions are recorded, because a criterion that was actively ruled out is a different thing from one that was never coded, and the primary documentation distinguishes the two.

For formal sensitivity and specificity figures, tell us at the first call which standard your regulatory colleagues work to and we will establish what your submission needs.

Next stepAsk for a completeness report on your own cohort.
How long does a real-world evidence study take?

Timeline depends on four things: how many patients, how deep the extraction goes, over what observation period, and which variables your endpoint requires. We scope all four in the first conversation.

What we commit to is the time to certainty. A named person replies to your question. A call establishes what the data supports. Under NDA you then see real structured records for your own cohort and check them yourself. None of that depends on scope, so none of it is an estimate.

Study delivery is scoped in writing against what the initial review showed, so the timeline you agree to is the timeline you get.

Next stepTell us what is stuck. On the first call you will know where the data can help.

Start with one question.

Send us one indication and one question. Under NDA you see real structured records for your own cohort, with a link to the source for every value, before anyone commits budget.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nothing is shared before an NDA is in place. No sales sequence follows.
Time is Health.
CLINICAL CARE